Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention

被引:95
作者
Pollak, MN
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Res Inst, Dept Oncol, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Lady Davis Res Inst, Dept Med, Montreal, PQ H3T 1E2, Canada
关键词
insulin-like growth factor I; IGF binding proteins; IGFBP proteases; growth hormone; GH/IGF-I axis; risk factors; endocrine therapy; prevention;
D O I
10.1023/A:1005950916707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Insulin-Like growth factors (IGFs) are mitogenic and anti-apoptotic peptides that influence the proliferative behavior of many cell types, including normal and transformed breast epithelial cells. IGF-I has properties of both a tissue growth factor and a systemic hormone: there is evidence that IGF bioactivity in tissues is influenced not only by local factors such as tissue expression of IGFs, IGF binding proteins (IGFBPs), and IGFBP proteases, but also by factors that regulate whole-body IGF physiology and circulating IGF-I levels. Experimental evidence that interventions that reduce circulating IGF-I levels reduce proliferation of breast neoplasms has raised interest in the possibility of developing novel endocrine therapies that target the growth hormone/IGF-I axis. Furthermore, influences of the growth hormone/IGF-I axis on normal breast epithelial cells may underlie recent epidemiological observations that suggest that premenopausal women with high circulating IGF-I level are at increased risk for breast cancer. These studies suggest that the growth hormone/IGF-I axis deserves investigation as a possible target for novel breast cancer prevention strategies.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 74 条
  • [1] ALBANES D, 1987, CANCER RES, V47, P1987
  • [2] BLOCKADE OF THE TYPE-I SOMATOMEDIN RECEPTOR INHIBITS GROWTH OF HUMAN-BREAST CANCER-CELLS IN ATHYMIC MICE
    ARTEAGA, CL
    KITTEN, LJ
    CORONADO, EB
    JACOBS, S
    KULL, FC
    ALLRED, DC
    OSBORNE, CK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) : 1418 - 1423
  • [3] ARTEAGA CL, 1989, CANCER RES, V49, P6237
  • [4] MAMMARY-CANCER IN TRANSGENIC MICE EXPRESSING INSULIN-LIKE GROWTH-FACTOR-II (IGF-II)
    BATES, P
    FISHER, R
    WARD, A
    RICHARDSON, L
    HILL, DJ
    GRAHAM, CF
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1189 - 1193
  • [5] INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEIN-3 IS DECREASED IN EARLY-STAGE OPERABLE PREMENOPAUSAL BREAST-CANCER
    BRUNING, PF
    VANDOORN, J
    BONFRER, JMG
    VANNOORD, PAH
    KORSE, CM
    LINDERS, TC
    HART, AAM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (03) : 266 - 270
  • [6] Co-expression of bovine growth hormone (GH) and human GH antagonist genes in transgenic mice
    Chen, NY
    Chen, WY
    Striker, LJ
    Striker, GE
    Kopchick, JJ
    [J]. ENDOCRINOLOGY, 1997, 138 (02) : 851 - 854
  • [7] CHEN WY, 1994, J BIOL CHEM, V269, P15892
  • [8] Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6
  • [9] COHEN SM, 1991, CANCER RES, V51, P6493
  • [10] CELL-PROLIFERATION IN CARCINOGENESIS
    COHEN, SM
    ELLWEIN, LB
    [J]. SCIENCE, 1990, 249 (4972) : 1007 - 1011